BD hospital infection settlement
This article was originally published in The Gray Sheet
Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...
You may also be interested in...
French diagnostic firm BioMérieux is attempting to renege on a licensing agreement with Becton Dickinson relating to methods for detecting one of the most common infections picked up in hospitals, according to BD
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.